OPXA - Opexa Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.9699
-0.1001 (-9.3551%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.0700
Open1.1500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.9600 - 1.1600
52 Week Range0.5000 - 3.5500
Volume307,280
Avg. Volume175,811
Market Cap7.43M
Beta2.09
PE Ratio (TTM)-1.34
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks4 months ago

    Company News for July 05, 2017

    Companies in the News are: RATE,EQT,MSDI,OPXA

  • TheStreet.com4 months ago

    Opexa Shares Jump on Merger with Acer Therapeutics

    After consummation Opexa's name will be changed to Acer Therapeutics Inc.

  • Benzinga4 months ago

    Merger Monday: 9 M&A Firecrackers Ahead Of Market Holiday

    Just ahead of Independence Day market closures, rumors and news abounded of mergers, from revived chatter of Walt Disney Co (NYSE: DIS ) for Verizon Communications Inc. (NYSE: VZ ) to new disruptions by ...

  • Opexa Therapeutics, Inc. :OPXA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 30, 2017
    Capital Cube7 months ago

    Opexa Therapeutics, Inc. :OPXA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 30, 2017

    Categories: Yahoo Finance Get free summary analysis Opexa Therapeutics, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Opexa Therapeutics, Inc. – Synthetic Biologics, Inc., Fortress Biotech, Inc., Momenta Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited Sponsored ADR (SYN-US, FBIO-US, MNTA-US and TEVA-US) that have also ... Read more (Read more...)

  • TheStreet.com9 months ago

    These 5 Stocks Under $10 Could Explode Higher Soon

    Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

  • Capital Cube10 months ago

    ETFs with exposure to Opexa Therapeutics, Inc. : December 23, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Opexa Therapeutics, Inc. Here are 5 ETFs with the largest exposure to OPXA-US. Comparing the performance and risk of Opexa Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube10 months ago

    ETFs with exposure to Opexa Therapeutics, Inc. : December 12, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Opexa Therapeutics, Inc. Here are 5 ETFs with the largest exposure to OPXA-US. Comparing the performance and risk of Opexa Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube11 months ago

    ETFs with exposure to Opexa Therapeutics, Inc. : December 1, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Opexa Therapeutics, Inc. Here are 5 ETFs with the largest exposure to OPXA-US. Comparing the performance and risk of Opexa Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube11 months ago

    ETFs with exposure to Opexa Therapeutics, Inc. : November 18, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Opexa Therapeutics, Inc. Here are 5 ETFs with the largest exposure to OPXA-US. Comparing the performance and risk of Opexa Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Opexa Therapeutics, Inc. :OPXA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016
    Capital Cube11 months ago

    Opexa Therapeutics, Inc. :OPXA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016

    Categories: Yahoo Finance Get free summary analysis Opexa Therapeutics, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Opexa Therapeutics, Inc. – Synthetic Biologics, Inc., Biogen Inc., Fortress Biotech, Inc., Momenta Pharmaceuticals, Inc., Novartis AG Sponsored ADR and StemCells, Inc. (SYN-US, BIIB-US, FBIO-US, MNTA-US, NVS-US and ... Read more (Read more...)

  • Biotech Movers on Thursday: Cempra Inc (CEMP) And Opexa Therapeutics Inc (OPXA)
    Insider Monkeylast year

    Biotech Movers on Thursday: Cempra Inc (CEMP) And Opexa Therapeutics Inc (OPXA)

    Another big day in the biotech sector? You bet. Things are hotting up across the space as the final quarter approaches mid-point, and we’ve had a number of catalysts and updates hit press over the last twenty-four hours that have had an impact on their respective entities. Here are two of the day’s biggest movers […]

  • 24/7 Wall St.last year

    6 Companies That Destroyed Shareholders Last Week

    The broad markets are holding steady near their double bottom set this summer. However, over the course of the past week this has been tested.

  • GNC Deal Could Be In Jeopardy, Genocea Taming Herpes, Opexa Not Taming MS, Plus The Latest on Theravance
    Insider Monkeylast year

    GNC Deal Could Be In Jeopardy, Genocea Taming Herpes, Opexa Not Taming MS, Plus The Latest on Theravance

    The SPDR S&P 500 ETF Trust (NYSEARCA:SPY) has gained 0.21% this morning, in lockstep with the S&P 500, as it is wont to do. The ETF, which is weighted as close as possible to the index, is gaining this morning on solid GDP data as well as the announcement of a potential partnership deal between […]

  • 24/7 Wall St.last year

    Is This the Beginning of the End of Opexa?

    Opexa Therapeutics Inc. (NASDAQ: OPXA) shares were in free fall Friday morning after the company reported results from its mid-stage trial for the treatment of secondary progressive multiple sclerosis. ...